Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Operations: 2020-2024

Historic Cash from Operations for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$34.3 million.

  • SAB Biotherapeutics' Cash from Operations fell 107.41% to -$13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.5 million, marking a year-over-year increase of 1.77%. This contributed to the annual value of -$34.3 million for FY2024, which is 36.52% down from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Cash from Operations is -$34.3 million, which was down 36.52% from -$25.1 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Cash from Operations high stood at $10.0 million for FY2020, and its period low was -$34.3 million during FY2024.
  • In the last 3 years, SAB Biotherapeutics' Cash from Operations had a median value of -$25.1 million in 2023 and averaged -$27.6 million.
  • Data for SAB Biotherapeutics' Cash from Operations shows a maximum YoY plummeted of 1,280.73% (in 2022) over the last 5 years.
  • SAB Biotherapeutics' Cash from Operations (Yearly) stood at $10.0 million in 2020, then slumped by 80.14% to $2.0 million in 2021, then plummeted by 1,280.73% to -$23.5 million in 2022, then dropped by 7.08% to -$25.1 million in 2023, then plummeted by 36.52% to -$34.3 million in 2024.